Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Structure Therapeutics Inc. - American Depositary Shares (NQ: GPCR )

37.08 +0.02 (+0.05%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 337,085
Open 37.32
Bid (Size) 35.50 (1)
Ask (Size) 37.50 (1)
Prev. Close 37.06
Today's Range 35.41 - 38.30
52wk Range 25.57 - 75.02
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. 
Via Benzinga
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q1 2024
GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-8.20%
-8.20%
1 Month
+1.78%
+1.78%
3 Month
-8.47%
-8.47%
6 Month
-28.03%
-28.03%
1 Year
+19.84%
+19.84%

More News

Read More
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
Via InvestorPlace
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Via InvestorPlace
7 Small-Cap Stocks that Wall Street Loves for Good Reason
Via InvestorPlace
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023
Via InvestorPlace
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
From Structure Therapeutics Inc.
Via GlobeNewswire
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
From Structure Therapeutics Inc.
Via GlobeNewswire
The Best-Performing U.S. IPOs Of 2023
Via Talk Markets
IPO watch 2024: Which new stocks will hit the market?
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Via Investor's Business Daily
Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now
Via The Motley Fool
7 Small-Cap Stocks That Wall Street Loves for Good Reason
Via InvestorPlace
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Nasdaq Gains 100 Points; Biomerica Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises 3%; US Housing Market Index Increases In December
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Novo Nordisk's Potential Obesity Drug Rival Structure Therapeutics Stock Tanking Today?
Via Benzinga
Dow Gains Over 50 Points; Nippon Steel To Acquire U. S. Steel
Via Benzinga
Topics Stocks
Exposures US Equities
Structure Stock Takes A Brutal Beating After Obesity Drug Trails Lilly's Leader
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
From Structure Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.